eli lilly oral tirzepatide weight loss drug data released Eli Lilly launched a four-dose,

In a 2021 study which directly compared tirzepatide with semaglutide, tirzepatide was found to have slightly higher incidences of troubling side effects

While GLP-1 RAs are less potent in BP reduction compared to conventional antihypertensive agents, the broader metabolic benefits of these agonists make this class of drug a valuable adjunct in managing hypertension, particularly in patients with metabolic syndrome

1.5 min)

While Ozempic is FDA-approved for Type 2 Diabetes, Wegovy is the same drug approved specifically for chronic weight management

Its dramatic effects on their lives is a sharp reminder that GLP-1 agonists are not the whole story of obesity